

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer (review of TA761) [ID5120]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (osimertinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Asthma and Lung UK • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • EGFR Positive UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Oncogene Cancer Research • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Thoracic Oncology Group • Cancer Research UK • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social care • NHS England • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • York Health Economics Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bristol Myers Squibb (paclitaxel) • Hospira (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) • Medac (vinorelbine) • Pierre Fabre (vinorelbine) • Sandoz (cisplatin) • Seacross Pharmaceuticals (docetaxel, paclitaxel) • Sun Pharmaceuticals (gemcitabine) • Synchrony Pharma (gemcitabine) • Teva (paclitaxel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • Cochrane Airways Group • Cochrane Lung Cancer Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute

Final stakeholder list for the single technology appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer (review of TA761) [ID5120]

Issue date: October 2023

© National Institute for Health and Care Excellence 2023. All rights reserved

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.